

Recombinant Human Fc gamma RIIIB/CD16b/NA1 His-tag


Catalog Number: 11652-FC

DESCRIPTION	
Source	Chinese Hamster Ovary cell line, CHO-derived human Fc gamma RIIIB/CD16b protein Gly17-Ser200, with a C-terminal 6-His tag Accession # O75015.3 Ser36Arg, Asn82Asp, Ile106Val
N-terminal Sequence Analysis	Gly17 & Met 18
Predicted Molecular	22 kDa

SPECIFICATIONS	
SDS-PAGE	33-45 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA. Recombinant Human Fc gamma RIIIB/CD16b/NA1 His-tag (Catalog # 11652-FC) binds Human IgG with an ED ₅₀ of 0.100-1.50 μg/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 250 μg/mL in water.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.	





Recombinant Human Fc gamma RIIIB/CD16b/NA1 Histag Protein SDS-PAGE. 2 µg/lane of Recombinant Human Fc gamma RIIIB/CD16b/NA1 Histag Protein (Catalog # 11652-FC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 33-45 kDa, under reducing conditions.

Rev. 5/20/2025 Page 1 of 2



Recombinant Human Fc gamma RIIIB/CD16b/NA1 His-tag

Catalog Number: 11652-FC

BACKGROUND

Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily. Based on their genetic organization and molecular structure, three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized (1 - 3). These receptors function in the activation or inhibition of immune responses. The activating-type receptor either has, or associates non-covalently with an accessory subunit (FcR γ or ζ chain) that has an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. In contrast, the inhibitory receptor (Fc γ RIIB) has a built-in immunoreceptor tyrosine-based inhibitory motif (ITIM) in its own cytoplasmic domain. Fc γ RI is a high-affinity receptor that binds monomeric IgG. Both Fc γ RIII and RIII are low-affinity receptors that bind IgG in the form of immune complexes. Two genes for human Fc γ RIII, A and B, encoding a transmembrane receptor and a glycosylphosphatidylinositol (GPI) anchored protein, respectively, have been identified. Three allelic variants of Fc γ RIIIB, NA-1, NA-2, and SH, exist. A soluble form of Fc γ RIIIB corresponding to the extracellular region of the receptor is produced by proteolytic cleavage and circulates in plasma and other body fluids. The extracellular domains of Fc γ RIIIA and B share 97% amino acid sequence homology. Whereas Fc γ RIIIA is expressed on most effector cells of the immune system including macrophage, monocyte, NK cells, mast cells, eosinophils, dendritic cells and Langerhans cells, Fc γ RIIIB is selectively expressed in neutrophils and eosinophils. Signaling through Fc γ RIIIA results in oxidative burst, cytokine release and phagocytosis by macrophages, antibody-dependent cellular cytotoxicity by natural killer cells and degranulation of mast cells. By contrast, Fc γ RIIIB is a decoy receptor that binds IgG complexes without triggering activation. Soluble Fc γ RIIIB has a regulatory role in inflammatory processes (4). It interacts with complement receptors CR3 and

References:

- 1. van de Winkel, J, and P. Capes (1993) Immunol. Today 14:215.
- 2. Ravetch, J.V. and S. Bolland (2001) Annu. Rev. Immunol. 19:275.
- 3. Takai, T. (2002) Nature Rev. Immunol. 2:580.
- 4. Gauchat, G.J. et al. (1996) J. Immunol. 157:1184.